Aerie Pharmaceuticals has submitted a prior approval supplement to the FDA to allow Rocklatan production in its Athlone, Ireland, facility, according to a press release.
Rocklatan (netarsudil 0.02% and latanoprost 0.005% ophthalmic solution) is indicated for the treatment of open-angle glaucoma or ocular hypertension.
“Along with the successful GMP inspection and authorization of the Athlone plant for product manufacturing by Ireland’s Health Products Regulatory Authority, we have also successfully executed process validation studies for Rocklatan and generated stability data to
Uncategorized